3 withdrawn. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine UB-612, Placebo - Covid-19, SARS-CoV-2 | Phase 2 / Phase 3 | Withdrawn | Vaxxinity, Inc. | 2021-02-01 | 2022-04-04 | |
| Convalescent Plasma to Limit Coronavirus Associated Complications Convalescent Plasma - Coronavirus | Phase 2 | Withdrawn | Mayo Clinic | 2020-04-01 | 2020-04-08 | |
| Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore Hydroxychloroquine - COVID, Coronavirus | Phase 2 | Withdrawn | Montefiore Medical Center | 2020-04-01 | 2020-05-27 |
COVID-19 (3) · Coronavirus Infections (3)
Coronaviridae Infections (3) · Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · RNA Virus Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Virus Diseases (3)
Hydroxychloroquine (1) · UB-612 COVID-19 vaccine (1)
Mayo Clinic (1) · Montefiore Medical Center (1) · Vaxxinity, Inc. (1)
United States (1)
Gray Heppner (1) · Michael Joyner, MD (1) · Priya Nori, MD (1)